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Peptide hormones can stimulate cyclic GMP synthe- 
sis through either of two general mechanisms: some 
peptides activate the cytoplasmic form of guanylate 
cyclase via a coupling factor called EDRF (endothe- 
lium-derived relaxation factor), while others activate 
the membrane form by interacting directly with an 
extracellular binding domain of the cyclase molecule 
itself. We have investigated the mechanism(s) by which 
crustacean hyperglycemic hormone (CHH), a neuro- 
peptide that regulates energy metabolism in crusta- 
ceans, elevates cyclic GMP levels in lobster muscle. 
Phosphodiesterase inhibitors potentiate the response 
in intact tissue. This indicates that the primary effect 
of the peptide is to activate a cyclase rather than inhibit 
a phosphodiesterase. Methylene blue, a specific inhib- 
itor of the EDRF pathway, does not block the actions 
of CHH. In addition, nitroprusside, an agent that di- 
rectly activates the EDRF pathway in vertebrate ani- 
mals, does not activate guanylate cyclase either in 
intact or homogenized lobster muscle. This indicates 
that the EDRF pathway, although prominent in ver- 
tebrate muscle, is not found in crustaceans and further 
suggests that the membrane cyclase is the most likely 
target of CHH. Membrane and soluble cyclases can be 
isolated from homogenates of lobster muscle (in a 3.5: 1 
ratio), and both are stimulated by Mn2+ and inhibited 
by Ca’+. CHH has no effect on the soluble enzyme. 
Coupling of CHH receptors to the particulate cyclase, 
however, remains intact in isolated membranes, thus 
providing a new model system for the study of receptor/ 
cyclase interactions. 
Cyclic GMP is an important second messenger in vertebrate 
and invertebrate muscle. Mammalian vascular smooth mus- 
cle, mammalian cardiac muscle, and the skeletal muscles of 
invertebrates, like the lobster, are enriched for cyclic GMP- 
dependent kinase and its substrates (Casnellie and Greengard, 
1974; Rapoport et al., 1982; Lincoln and Johnson, 1984; KUO 
and Greengard, 1970; Goy et al., 1984). Furthermore, specific 
stimuli elevate cyclic GMP levels in these tissues. In verte- 
brate animals, a variety of vasodilating hormones raise cyclic 
GMP levels and subsequently induce vascular and cardiac 
relaxation (reviewed in Waldman and Murad, 1987; Tremblay 
et al., 1988; and Fischmeister and Hartzell, 1987). In the 
lobster and other crustaceans, a peptide hormone called crus- 
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tacean hyperglycemic hormone (CHH)’ raises muscle cyclic 
GMP levels (Sedlmeier and Keller, 1981; Goy et al., 1987a; 
Pavloff and Goy, 1990), stimulates muscle glycogen metabo- 
lism (Keller and Andrew, 1973), and may also relax hormone- 
or depolarization-induced muscle contraction (Goy et al., 
1987b). 
In vertebrates, at least three different enzymes control 
tissue levels of cyclic GMP. 1) A membrane-specific form of 
guanylate cyclase is regulated in many tissues, including vas- 
cular smooth muscle, by the members of the atria1 natriuretic 
peptide (ANP) family (Waldman et al., 1985; Leitman and 
Murad, 1987). The family includes a set of homologous pep- 
tides produced by the atrium of the heart and related forms 
produced in the brain (Seidah et al., 1984; Tanaka et al., 1984; 
Saper et al., 1985; Sudoh et al., 1988). These peptides selec- 
tively turn on the membrane cyclase, probably by interacting 
with an extracellular binding domain of this membrane-span- 
ning enzyme (Schulz et al., 1989). 2) A Cytoplasmic form of 
guanylate cyclase is activated in many tissues, again including 
vascular smooth muscle, by an endogenous regulatory mole- 
cule called endothelium-derived relaxation factor (EDRF). In 
the case of smooth muscle, EDRF is produced in the vascular 
endothelium in response to a variety of hormones, including 
the peptides bradykinin, cholecystokinin, substance P, throm- 
bin, and calcitonin gene-related peptide (Griffith et al, 1988). 
Once produced by the endothelium, EDRF diffuses into the 
cytoplasm of nearby smooth muscle cells (limited primarily 
by the relatively short half-life of the EDRF molecule), where 
it directly stimulates the soluble cyclase. 3) A cyclic GMP- 
specific phosphodiesterase is regulated by light in vertebrate 
photoreceptors (reviewed in Stryer, 1986). The capture of a 
photon of light activates the phosphodiesterase via a GTP 
binding protein (transducin), which in turn produces a de- 
crease in photoreceptor cyclic GMP levels. 
The present study is directed toward identifying the mech- 
anism(s) by which CHH regulates cyclic GMP metabolism in 
lobster exoskeletal muscle. Because of similarities between 
this tissue and vertebrate vascular smooth muscle, we were 
particularly interested in seeing whether CHH would act 
through the membrane cyclase, as do the peptides in the ANP 
family, or via EDRF and the soluble cyclase, as do other 
vertebrate peptides such as bradykinin. We have also inves- 
tigated the possibility that CHH raises cyclic GMP levels in 
lobster muscle by inhibiting the cyclic GMP-specific phos- 
phodiesterase (the converse of the effects of light in retinal 
photoreceptors). 
1 The abbreviations used are: CHH, crustacean hyperglycemic hor- 
mone; EDRF, endothelium-derived relaxation factor; BSA, bovine 
serum albumin; IBMX, isobutyl methylxanthine; HPLC, high pres- 
sure liquid chromatography; ANP, atria1 natriuretic peptide( 
HEPES, 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid. 
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MATERIALS AND METHODS concentration of methylene blue. After an additional 90 min, the 
muscle nieces were frozen and processed as above. 
Preparation of Crude and Purified CHH-CHH is produced by the 
sinus gland, a well known crustacean neurohemal organ (Keller et al., 
1985). In the lobster, as in other crustaceans, two forms of CHH have 
been identified.’ The major form (called peptide G1 in previous 
studies) has been purified (Pavloff and Goy, 1990) and its sequence 
is comparable to that recently established for CHH purified from the 
crab (Kegel et al., 1989). The minor form, comprising about 10% of 
the total activity, appears to be closely related to the major form, 
perhaps differing by-only one or two amino acids (see Newcomb, 
1983. and Huberman and Aauilar, 1986). These two isoforms of CHH 
are the only molecules present in the sinus gland with significant 
stimulatory effects on cyclic GMP metabolism.’ 
For the current studies, sinus glands were identified and dissected 
as described previously (Goy et al., 1987a). Crude CHH-containing 
extracts were prepared by homogenizing the glands in a bioassay 
medium consisting of lobster saline (462 mM NaCl, 16 mM KCl, 26 
mM CaCh, 8 mM MgCh, 11 mM glucose, 10 mM Tris maleate, pH 7.4) 
with 1 mM EDTA. 0.1 mM nhenvlmethvlsulfonvl fluoride. and 0.1 
-  1  
mM o-phenanthrohne as protease inhibitors, and 1 mg/ml bovine 
serum albumin (BSA). Before use, the homogenate was centrifuged 
for 20 min in a Beckman Microfuge (8000 x g) to remove particulate 
material. 
Purified CHH was prepared from crude sinus gland extracts by 
sequential ion exchange and reverse phase high pressure liquid chro- 
matography (HPLC), as described byPavloff andGoy (1990). Purified 
material from the final HPLC stea was diluted into distilled water 
containing BSA, lyophilized to dryness to remove HPLC solvents, 
and resuspended in bioassay medium or Buffer A, as described below. 
The approximate concentration of CHH was determined from the 
estimated molecular weight of the peptide and the results of amino 
acid analysis on an aliquot of the purified material. 
Bioassay in Intact Muscle-The effects of CHH on cyclic GMP 
metabolism in intact muscle tissue were evaluated using a previously 
described assay (Goy et aZ., 1987a). To compare the response in the 
presence and absence of a phosphodiesterase inhibitor, individually 
dissected pieces of muscle were preincubated for 2 h either in lobster 
saline or in saline containing 0.5 mM isobutyl methylxanthine 
(IBMX). This preincubation was performed to allow cyclic GMP 
levels to reach steady state after IBMX treatment (about 3- to &fold 
above control), so that changes in cyclic GMP levels due to the 
phosphodiesterase inhibitor would not be superimposed on those due 
to the peptide. Each piece of tissue was then transferred to bioassay 
medium (approximately 0.2 ml/muscle) containing a specified con- 
centration of CHH, either with or without IBMX and other phar- 
macological reagents, as appropriate. After an additional period of 
incubation (as indicated in the figures), the pieces of tissue were 
briefly rinsed in saline (to wash away BSA from the incubation 
medium), frozen, and homogenized in trichloroacetic acid. Each ho- 
mogenate was then centrifuged, to yield a soluble fraction (containing 
cyclic GMP) and an insoluble fraction (containing protein). The 
cyclic GMP levels were determined by radioimmunoassay (reagents 
and procedures obtained from Biomedical Technologies Incorporated, 
Stoughton, MA) and corrected for the size of the piece of muscle 
(determined by measuring protein in the trichloroacetic acid pellet, 
according to the method of Lowry et al. (1951)). 
The effects of the guanvlate cvclase inhibitor (methvlene blue) 
were evaluated in intact tissue by preincubating pieces of muscle for 
105 min in saline containing 0.5 mM IBMX, followed by an additional 
15 min in saline with IBMX and varying concentrations of methylene 
blue (ranging from none to 2 mM). Muscle pieces were then trans- 
ferred to bioassay medium containing CHH and the appropriate 
’ M. F. Goy, manuscript in preparation. 
a Proloneed incubation in IBMX has no deleterious effects on nerve 
or muscle as judged by measurement of membrane potential, input 
resistance, excitatory postsynaptic potential amplitude, and sponta- 
neous miniature synaptic potential amplitude (Goy and Kravitz, 
1989). A reduction in depolarization-evoked muscle contraction is 
observed, but we believe this is the normal response of the muscle to 
elevated cyclic GMP levels (Goy et al., 1987b). However, to ensure 
that the results obtained in the current study do not reflect some 
unusual side effect due to lengthy exposure to IBMX, we have also 
measured the time course of the cyclic GMP response after simulta- 
neous exposure to IBMX and peptide. When the effects due to IBMX 
alone are subtracted, the response is identical with that of Fig. lb 
(data not shown). 
The effects of the guanylate cyclase activator (sodium nitroprus- 
side) were determined bv treating muscle (ureincubated with IBMX) 
for times ranging froml”min to 90 min with concentrations of nitro- 
prusside ranging from none to 50 mM. 
Guunylate Cyclase Assay in Muscle Homogenates-In order to eval- 
uate the properties of guanylate cyclase in muscle homogenates, the 
assay of Leitman et al. (1987) was adapted. For this assay, either tail 
muscle or the opener muscle of the dactyl of the walking leg was used. 
After dissection under cold saline, muscles were rinsed once with cold 
buffer B (50 mM HEPES, pH 7.4, with 1 mM EDTA, 0.01% bacitracin, 
and 0.1 mM phenylmethylsulfonyl fluoride) and then homogenized in 
ice-cold buffer B (1 ml of buffer/O.5 g of tissue wet weight) using a 
motor-driven Potter-Elvehjem homogenizer with a nylon pestle. After 
removing a portion of this material (crude cyclase), the remainder 
was centrifuged for 60 min at 100,000 X g (4 “C). The upper two- 
thirds of the supernatant were carefully removed (to yield the soluble 
cyclase preparation). Earlier studies have shown that the cytoplasmic 
fraction generated by this procedure contains less than 1% of the 
membrane lipid initially present in the crude homogenate (Goy et al., 
1984). The remainder of the supernatant was then discarded and 
Buffer C (Buffer B + 100 mM KCl) was used to resuspend the pellet 
(3 ml of buffer/O.5 g of initial tissue wet weight). The resuspended 
material was again centrifuged for 60 min at 100,000 X g (4 “C), and 
the new pellet was resuspended by homogenization in Buffer B (3 
ml/O.5 g of initial tissue wet weight) and subjected to a third centrif- 
ugation for 60 min at 100,000 X g (4 “C). This final pellet (membrane 
cyclose) was resuspended in Buffer B to the same volume as the 
soluble cyclase fraction. All resuspensions were by homogenization. 
Each fraction was either frozen immediately (see below) or stored on 
ice until it could be assayed for activity, usually within 10 min. 
Protein content was determined on an aliquot of each fraction by the 
method of Lowry et al. (1951). The amounts of protein obtainable 
from 0.5 g wet weight of tissue (the approximate wet weight of a 
single dactyl opener muscle) are 111.8 f 2.3 mg of protein as a crude 
homogenate (n = 3, rtS.E.), or 24.8 ? 3.4 mg in the soluble preparation 
(n = 7, *SE.) plus 51.2 + 4.0 mg in the membrane preparation (n = 
8, &S.E.). 
In some cases, large membrane preparations were divided into 
aliquots and rapidly frozen on dry ice. Frozen aliquots could be stored 
up to 12 months and thawed without noticeable loss of activity. No 
consistent differences were observed between tail and dactyl opener 
muscle or between fresh and frozen tissue. We did note some deteri- 
oration if membranes were held on ice for periods of hours, and this 
deterioration appeared to accelerate if the temperature was raised. 
To initiate cyclase activity, aliquots of each of the muscle fractions 
were rapidly mixed with equal volumes of freshly made, room tem- 
perature Buffer A (50 mM HEPES, pH 7.4, with 8 mM MgClz, 2 mM 
IBMX, 4 mM GTP, 60 mM phosphocreatine, 800 fig/ml creatine 
kinase (185 units/mg), and 1 mg/ml BSA). At various times there- 
after, 40.~1 samples were removed, pipetted into 100 ~1 of 6% trichlo- 
roacetic acid (w/v), vortexed immediately, and placed on ice. Trichlo- 
roacetic acid was used as a stopping agent, because the boiling 
procedure of Leitman et al. (1987) was found to generate artifacts. A 
“zero” time point was prepared for each condition by premixing 20 ~1 
of Buffer A with 100 ~1 of trichloroacetic acid, and then adding 20 ~1 
of the appropriate muscle fraction. When the effects of ions, meth- 
ylene blue, nitroprusside, or purified CHH were tested on homogenate 
fractions, these agents were added to the Buffer A diluent where 
appropriate, at twice the desired final concentration. Final free con- 
centrations of divalent cations were calculated using the Eqcal pro- 
gram (Biosoft, Cambridge UK), with dissociation constants from 
Martell and Smith (1974,1975). 
The cyclic GMP content of each time point was determined by 
radioimmunoassay, as in the procedure described above for intact 
tissues. Each sample was extracted four times with 3 volumes of 
diethyl ether, to remove the trichloroacetic acid, then diluted as 
required (usually from 1:2 to 1:50), and acetylated prior to assay. The 
results are usually expressed as picomoles of cyclic GMP synthesized 
per mg of protein (to correct for differences in protein recovery 
between experiments). In contrast to the bioassay in intact tissues, 
which displays considerable variability from point to point and ex- 
periment to experiment (Goy et al., 1987a), the data obtained from 
homogenized preparations are quite reproducible. The average vari- 
ability of duplicate points in 80 randomly chosen determinations is 
7.5%, approximately half the variability observed with intact tissues. 
The variation from experiment to experiment is also significantly 
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decreased. This improvement in reproducibility is probably due to 
the elimination of muscle to muscle or animal to animal differences. 
Vertebrate Tissues-A Z-cm piece of aorta (0.11 g wet weight) was 
removed from an adult male Sprague-Dawley rat under urethane and 
cu-chloralose anesthesia (425 and 100 mg/kg intraperitoneally). The 
tissue was homogenized in 1 ml of cold Buffer B, and the crude 
homogenate was used at once in the guanylate cyclase assay described 
above. 
Dorsal root ganglia were removed from embryonic rats (day E16- 
17), dissociated, and grown for 7 days in tissue culture, as described 
by Gammon et al. (1989). Cultures were placed at room temperature 
and treated for 1 min with either control saline (145 mM NaCl, 5 mM 
KCl, 2 mM CaCb, 1 mM MgC&, 10 mM glucose, and 10 mM HEPES, 
pH 7.4) or saline containing 0.3 mM nitroprusside. The saline was 
then replaced with 1.5 ml of 6% trichloroacetic acid, cells were scraped 
from the dish, and the trichloroacetic acid soluble and insoluble 
fractions were analyzed for cyclic GMP and protein, respectively, as 
described above. 
Chemicals and Supplies-EDTA, HEPES, bacitracin, phenylmeth- 
ylsulfonyl fluoride, o-phenanthroline, IBMX, GTP, creatine kinase, 
phosphocreatine, methylene blue, nitroprusside, and bovine serum 
albumin were obtained from Sigma; HPLC solvents and trichloroa- 
cetic acid from J. T. Baker and Fisher; and radioimmunoassay kits 
for cyclic GMP from Biomedical Technologies Incorporated. 
M&B22948 was the generous gift of Dr. H. Gerschenfeld (Ecole 
Normale Superieure, Paris, France). All other chemicals and solvents 
were reagent grade, obtained from commercial sources. Lobsters were 
purchased from commercial suppliers and held at 12-14 “C in artifi- 
cial seawater, usually for at least a week prior to use. 
RESULTS 
Phosphodiesterase Inhibitors Amplify the Effects of CHH in 
Intact Tissues 
A first step toward understanding regulation of cyclic GMP 
metabolism in lobster tissues is to define the mechanism(s) 
by which CHH increases cyclic GMP levels. In general, CHH 
might act either by stimulating the rate of synthesis of cyclic 
GMP (by activating one of the forms of guanylate cyclase) or 
by reducing its rate of breakdown (by inhibiting phosphodi- 
esterase). One way to distinguish these two classes of mech- 
anisms is to compare the response of the target tissue in the 
presence and absence of a phosphodiesterase inhibitor. If the 
peptide stimulates cyclase, then the magnitude of the response 
should be increased by the inhibitor, whereas if it inhibits 
phosphodiesterase the response should be decreased. 
As seen in Fig. la, the response to CHH by intact muscle 
is greatly potentiated by the phosphodiesterase inhibitor 
IBMX, both at saturating and subsaturating levels of peptide. 
A similar result (not shown) was obtained with a second 
phosphodiesterase inhibitor, M&B22948, thought to be more 
selective for the form of phosphodiesterase that preferentially 
breaks down cyclic GMP (Bergstrand et al., 1977). Thus, the 
primary effect of the peptide is probably to stimulate cyclase 
rather than to inhibit phosphodiesterase. 
The initial rate of the response to CHH in intact tissues is 
roughly linear, both in the presence and absence of IBMX 
(Fig. lb). Over a period of 20-50 min, however, a plateau is 
attained. Presumably, this represents the new equilibrium 
level attained as a result of enhanced synthesis in the presence 
of the peptide. The plateau level is maintained with only a 
slight decline for as long as the peptide is present (up to 180 
min). This suggests that if the CHH receptor desensitizes, it 
does so only at a slow rate. 
When the peptide is washed away, the elevated levels of 
cyclic GMP begin to fall (Fig. lc). The time course of recovery, 
however, is not simple. Initially, the rate of cyclic GMP 
breakdown after peptide washout is relatively rapid. This is 
followed by an extended period (commencing about 50 min 
after washout) in which the rate of decline is much slower. 
The biochemical basis for the biphasic nature of the recovery 
process is not understood. We have noted, however, that 
during the late phase the tissue is capable of responding 
normally to a new application of peptide (added at the arrow 
in Fig. lc). 
Because CHH is a very hydrophobic molecule (Pavloff and 
Goy, 1990), we considered the possibility that the washing 
procedure might fail to completely remove the peptide from 
binding sites within the tissue. If so, then subsequent slow 
release of nonspecifically bound peptide could have produced 
a low level of free peptide, thereby keeping the level of cyclic 
GMP elevated above baseline. However, when we subjected 
tissues to a second washing step 25 min after the initial wash, 
the subsequent decline of cyclic GMP levels could not be 
distinguished from that of tissues that had only received the 
initial wash (compare filled and open circles at 260 min in Fig. 
lc). Thus, the late phase of the recovery process probably 
does not result from incomplete removal of the peptide. 
In all of the experiments in Fig. 1 we have used both purified 
CHH (square symbols) and an unpurified CHH-containing 
extract made from the sinus gland (circular symbols). The 
results are essentially identical in either case, which suggests 
that there are no additional hormonal agents produced by the 
sinus gland whose function is to modify the CHH response. 
CHH Activates a Guanylate Cyclase in Muscle Homogenates 
Establishing an Assay for Lobster Guanylute Cyclose-Be- 
cause the results in the preceding section suggest that CHH 
is likely to act by increasing the rate of cyclic GMP synthesis, 
we attempted to directly measure guanylate cyclase activity 
in fractionated lobster tissues. The assay that we used is based 
on methods that have been successfully applied to homoge- 
nates of vertebrate tissues (Leitman et al., 1987). The ability 
to quantitatively measure cyclase activity is demonstrated by 
several features of the assay. 1) Cyclic GMP synthesis is 
linear for at least 30 min (Figs. 2a and 4). We believe that 
this approximates the true rate of synthesis, since high levels 
of IBMX significantly block the enzymatic contribution of 
phosphodiesterases. Although it is possible that the lobster 
preparation contains an IBMX-insensitive phosphodiester- 
ase, we consider this unlikely because no such enzyme has 
been reported in the literature (Beavo, 1988). 2) The response 
reflects the rate at which the cyclase enzymes are working 
rather than limitations imposed by the availability of sub- 
strate. As shown in Fig. 2a, cyclic GMP synthesis is not 
stimulated by doubling the levels of GTP in the reaction 
mixture. 3) Synthesis can be stimulated, however, by increas- 
ing the amount of tissue in the incubation mix. Fig. 2b shows 
the rate of synthesis obtained as the concentration of purified 
membranes is varied. The response is proportional to the 
relative dilution, as expected if the assay accurately reflects 
the level of enzyme activity. All other experiments reported 
in this study were performed at rates of synthesis below 0.2 
pmol of cyclic GMP/min/40-pl sample, well within the range 
of demonstrated linearity. 4) As in vertebrate animals, the 
activity of the lobster enzymes can be enhanced by Mn*+ 
(Figs. 2c and 3). This further establishes that cyclic GMP 
synthesis under basal conditions is not substrate-limited. 
Characterization of Membrane and Cytoplasmic Forms of 
Cyclase-When high speed centrifugation is used to prepare 
soluble and particulate fractions of muscle homogenates, the 
fractions each contain substantial guanylate cyclase activity. 
The specific activity of the membrane cyclase is 0.275 + 0.065 
pmol of cyclic GMP synthesized/min/mg of protein (mean + 
S.E., n = 29), while that of the cytoplasmic cyclase is 0.158 f 
0.030 pmol of cyclic GMP synthesized/min/mg of protein 
(mean f S.E., n = 19). Since there is approximately twice as 
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FIG. 1. Effects of IBMX on the magnitude and time course of the CHH response in intact muscle. a, 
IBMX potentiates the response to sinus gland extracts (M, U) or purified CHH (U--D, M) at 
both saturating and subsaturating levels. Muscles were preincubated either with (filled symbols) or without (open 
symbols) IBMX and then treated with peptide at the indicated dilutions. Levels of cyclic GMP were determined 
after 90 min of additional incubation, as described under “Materials and Methods.” Each determination was made 
in duplicate (crude extract) or triplicate (purified peptide), and the error bars report the range or the SE. The 
lines were fitted by eye. b, time course of the response in the presence and absence of IBMX. Muscles were 
preincubated as in (a), then exposed to a subsaturating dose of sinus gland extract (C--O, 
U, at 0.08 gland/ml) or purified peptide (W, c--l, at 7 pmol/ml), either with (filled symbols) or 
without (open symbols) IBMX. At the times indicated, individual muscles were removed and their cyclic GMP 
content was determined. Each point is the mean (&S.E.) of 3 to 10 determinations, pooled from 3 separate 
experiments. The individual experiments, each of which was performed with muscles from a single animal, closely 
resemble the composite data. The lines were fitted by eye. c, reversal of the response following removal of the 
peptide. A detailed time course was determined only in the absence of IBMX, since, as expected from its role as a 
phosphodiesterase inhibitor, IBMX dramatically retards the recovery process (data not shown). Muscles were 
stimulated for 40 min with a subsaturating dose of sinus gland extract (O--0) or purified peptide (W). At 
the end of the stimulation period (time = 0), muscles were washed for 3 min with saline (3 rinses at 10 ml/rinse), 
in order to remove the peptide, and samples were taken at the indicated intervals. The solid line was fitted by eye. 
For purified and crude peptide, respectively, each point is the mean (+_S.E.) of 9 (or 12) determinations, pooled 
from 3 (or 4) separate experiments. As in b, each individual experiment closely resembles the composite. In all 7 
experiments, the last data point remains significantly above baseline (indicated by the horizontal dashed line). To 
see if this prolonged effect on cyclic GMP levels is due to residual peptide not removed by the washing procedure, 
we subjected 3 muscles to an additional 3 washes 25 min after the initial wash and measured their cyclic GMP 
levels 245 min later (M); see text. In one experiment, we also subjected three washed muscles to a second 
exposure to purified peptide at 160 min (upward arrow) and measured their cyclic GMP levels 40 min later 
m---m. 
much protein recovered in the particulate fraction as in the 
cytoplasmic fraction, the average ratio of membrane to soluble 
cyclase in intact tissue is calculated to be about 3.5:1. We 
have noted, however, that the recovery of membrane cyclase 
is much more variable from preparation to preparation than 
is the recovery of cytoplasmic cyclase (the standard deviation 
as a percent of the mean for the former is nearly twice as 
great as that for the latter). The reason for this is not yet 
known. It is possible that the membrane cyclase is up- or 
down-regulated in response to some environmental signal (for 
example, the molt cycle or the season) and thus varies from 
animal to animal, while the cytoplasmic cyclase remains rel- 
atively insensitive to such forms of regulation. Alternatively, 
the membrane cyclase may be more susceptible to losses 
during handling than the cytoplasmic cyclase, and its recovery 
therefore more variable. In favor of this latter interpretation, 
we have observed that cyclic GMP synthesis with the soluble 
enzyme is linear over the longest intervals tested (up to 210 
min), while the membrane enzyme consistently inactivates 
with time. The rate of inactivation is somewhat variable, but 
usually complete within 60 to 90 min (see Figs. 2a and 4). 
When tested separately, each form of the cyclase is stimu- 
lated by Mn2+ and inhibited by Ca*+ (Figs. 2c and 3). In 
contrast to some systems, where Ca*+ has dissimilar actions 
on the membrane and soluble forms of the enzyme (reviewed 
in Goldberg and Haddox, 1977), no differential effects are 
observed in the lobster. Inhibition by Ca*+ may play some 
part in the physiological regulation of lobster cyclase activity, 
since the threshold for its effect (1.5 X lo-” M) is within the 
range that can be attained by cells under normal conditions. 
It is not known whether inhibition results from a direct 
interaction of the ion with the cyclase molecules or indirectly 
via some other enzyme (such as a Ca2+-dependent kinase or 
protease). 
Effect of CHH on Membrane and Cytoplasmic Cychses- 
When either crude sinus gland extracts or purified CHH are 
included in the guanylate cyclase assay, they markedly and 
reproducibly enhance the activity of the membrane form of 
the enzyme, with little or no effect on the soluble form (Fig. 
4). The average effect of crude sinus gland extract on cyclase 
activity (measured after 30 min of exposure at a concentration 
of 0.175 gland/ml, approximately the EC&) is 273 f 43% of 
the control level for isolated membranes (mean f S.E., n = 
9) and 101 f 3% of the control level for isolated cytoplasm 
(mean f S.E., n = 5). Under the same conditions, purified 
CHH at 0.3 pmol/ml (approximately the EC&) raises mem- 
brane cyclase activity to 299 f 53% of the control rate (mean 
f S.E., n = 3) while again having no effect on isolated 
cytoplasm (100 f l%, n = 2). The lack of an effect on the 
soluble enzyme is probably not an artifact resulting from 
saturation of some step in the pathway, since Mn*+ can 
stimulate the soluble enzyme more than 3-fold above its basal 
rate (Fig. 3). 
As mentioned above, the effect of the peptide on the mem- 
branes is unlikely to result from inhibition of a phosphodies- 
terase, since the assay mixture contains high levels of IBMX. 
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time (min) 
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3. 
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0 2 4 6 8 10 
time (min) 
FIG. 2. Basic properties of the guanylate cyclase assay in 
muscle homogenates. Data are from experiments with isolated 
membranes. Similar data (not shown) may be obtained with crude 
homogenates or with isolated cytoplasm. a, linearity of the response 
at st.andard (2 mM, w) and elevated (4 mM, W) GTP 
levels. Each data point for the time course at 2 mM GTP is the mean 
(*SE.) of 3 to 6 determinations from 3 separate experiments. The 
data points at 4 mM GTP are the mean (H.E.) for 3 determinations 
made during one of the 2 mM experiments. The line was fitted by 
linear regression to the pooled 2 and 4 mM data (for incubation times 
of 60 min or less), with a correlation coefficient (R’ value) of 0.978. 
When the two sets of data were fitted separately, there was a small 
decrease (12%) in the rate at 4 mM GTP compared to that at 2 mM. 
We do not know if this slight apparent inhibition is significant. b, the 
rate of cyclic GMP synthesis is dependent on the amount of mem- 
brane added to the assay. Each point gives the rate of synthesis at a 
single concentration of protein. Rates were obtained by measuring 
cyclic GMP levels in duplicate at 0, 10, and 20 min of reaction time, 
then determining the slope of a line fitted to these data points by 
linear regression. In all cases, the correlation coefficients for the fitted 
lines were greater than 0.95. Data were obtained on 2 days, using 
aliquots frozen from a single batch of membranes with particularly 
high cyclase activity (approximately 0.4 pmol/min/mg of protein). 
The line drawn in the figure was determined by linear regression 
analysis of the rates as a function of protein concentration (correla- 
tion coefficient = 0.93). c, the rate of cyclic GMP synthesis is 
stimulated by Mn*+ (M) and inhibited by Ca2+ (A-A). Each 
point is the mean (*range) of duplicate determinations made in a 
single experiment. Lines were fitted by linear regression. 
-6 -5 -4 -3 -2 
log free ion concentration (M) 
FIG. 3. Comparison of the Ca2+ (Cl--U, U) and Mn2+ 
(O--O, U) sensitivity of the membrane cyclase (filled 
symbols) and soluble cyclase (open symbols). As in Fig. 26, rates 
were obtained from linear regression analysis of several time points 
in the 0-ZO-min range. The correlation coefficients of the fitted lines 
were usually above 0.96 and always greater than 0.85. The control 
rate (no added ions) is defined as 100%. The figure shows the averaged 
results of 3 experiments for each ion (mean f S.E.). 
These results, therefore, provide strong evidence that the 
peptide can activate a membrane-bound form of guanylate 
cyclase. The properties of the response of the purified mem- 
branes are consistent with those in the intact cell, except that 
the efficiency of coupling of receptors to cyclase appears to 
be reduced in the homogenate. In intact cells, when tested at 
the EC&, the peptide can cause 50- to loo-fold increases in 
cyclic GMP levels (Fig. 1, and Goy et al., 1987a). In contrast, 
at the EC&,,, the peptide causes only a 2- to 3-fold stimulation 
of cyclic GMP synthesis in homogenates (see above and Fig. 
4). A similar disparity in the magnitude of the response of 
intact compared to homogenized tissues has been noted for 
the ANP-sensitive cyclase obtained from vertebrate sources 
(Hamet et al., 1986). 
Investigation of a Possible Contribution of the Soluble Cyclase 
The results in the preceding section demonstrate that CHH 
can activate membrane-bound cyclase, but do not rule out the 
possibility that, in the intact cell, it also activates cytoplasmic 
cyclase. The failure to observe an effect, on the soluble enzyme 
in the homogenate studies may simply reflect the fact that 
the receptors for the peptide are associated with the mem- 
brane, and hence cannot interact with soluble cyclase after 
fractionation. This idea is somewhat attractive, since it could 
explain why the response in the intact cell is larger than the 
response in purified membranes. 
In vertebrates, the only definitively characterized route for 
activation of the soluble cyclase is the EDRF pathway. The 
identity of EDRF is somewhat controversial. Among the 
leading contenders are nitric oxide (Palmer et al., 1987; Ig- 
narro et al., 1987) and nitrocysteine (Myers et al., 1990). Once 
released, EDRF appears to stimulate the activity of the soluble 
cyclase through the transfer of electrons, perhaps to a heme 
group associated with the enzyme (Craven and DeRubertis, 
1978). Several pharmacological tools have proven useful in 
the investigation of EDRF-dependent processes (Furchgott 
and Vanhoutte, 1989). Methylene blue, a potent electron 
acceptor, can be used to intercept receptor-induced EDRF 
molecules before their electrons reach and activate the cyclase 
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FIG. 4. Comparison of the CHH sensitivity of the membrane and soluble cyclases. Time course for the 
membrane (a) and soluble (b) cyclases with (w, U) and without (o--O, a--O) a subsaturating 
dose of purified CHH (squares) or sinus gland extract (circles). Each point is the mean (&range) for 2 determinations. 
These results have been confirmed by many additional experiments. See text for details. 
molecule. Nitroprusside, which breaks down spontaneously to 
produce nitric oxide, can be used to activate the pathway in a 
receptor-independent manner. Therefore, if CHH acts in part 
through the generation of EDRF, then methylene blue should 
inhibit that part of the response while nitroprusside should 
mimic it. 
Fig. 5a shows the effect of methylene blue on the response 
to CHH. Not only is there no block of the peptide-induced 
cyclic GMP increase, but, somewhat surprisingly, methylene 
blue actually potentiates the response in intact tissue. The 
potentiation is not due to an unexpected stimulatory effect of 
methylene blue on the cyclase, because methylene blue alone 
appears to decrease the basal level of cyclic GMP (Fig. 5a, 
+methylene blue). We do not know why methylene blue 
enhances the response to CHH. However, despite this com- 
plication, it is quite clear that no inhibition occurs. This result 
is consistent with earlier experiments demonstrating that 
CHH-stimulated cyclic GMP synthesis in intact muscle is 
Ca’+-independent (Goy et al., 1987a), while EDRF-stimulated 
cyclase activity in intact vertebrate tissues requires the pres- 
ence of extracellular Ca’+ (Waldman and Murad, 1987). 
Taken together, the Ca*+ and methylene blue results strongly 
suggest that the EDRF pathway does not mediate the effects 
of CHH. 
In further support of this idea, Fig. 5b shows that intact 
lobster muscle fails to elevate cyclic GMP levels when treated 
with nitroprusside at a concentration more than 50-fold above 
that needed to activate the soluble cyclase in vertebrate 
tissues. We have also tested nitroprusside on intact lobster 
muscle at a variety of lower concentrations and for times 
ranging from 1 to 90 min, in all cases without effect (data not 
shown). As a control for the possibility that nitric oxide was 
produced by the nitroprusside but was unable to enter the 
cytoplasm to interact with the soluble cyclase, we applied 
nitroprusside to a broken cell preparation. Fig. 512 shows that 
the activator has no effect in a crude homogenate of lobster 
muscle (which contains both membrane and soluble cyclases). 
As positive controls, we have demonstrated that nitroprusside 
has the expected effect on cyclic GMP synthesis both in intact 
rat sensory neurons (Fig. 5b) and in homogenized rat smooth 
a negative control intnct ds 
+ metbykne blue 
+ sinus gland extract 
+ sinus gland extract 
+ metbykne blue 
+ purifkd CHli 
+ purilied CW 
+ methykne blue Eil 
0 10 20 30 
t 
= 0 
-NP +NP -NP +NP 
rat DRG neurons lobster mu~ck 
FIG. 5. Effects of methylene blue and nitroprusside on 
cyclic GMP metabolism in various cell types. a, failure to inhibit 
the response to CHH in intact lobster muscle with metbylene blue 
(see “Materials and Methods” for details). Each bar is the mean (& 
S.E.) of 3 to 9 determinations from 3 separate experiments. Crude 
and purified peptides were used at a subsaturating level, to ensure 
that inhibition, if it occurred, would be apparent. The concentration 
of methylene blue (1 mM) is lo- to loo-fold above that needed to 
cause complete inhibition of EDRF-mediated responses in vertebrate 
tissues (Gruetter et al., 1979; Garthwaite et al., 1988). b, cultured rat 
sensory (DRG) neurons or intact lobster muscles were exposed to 
nitroprusside at 0.3 mM (+NP) or a control solution (-NP) for 5 
min. Cells were then treated with trichloroacetic acid, and cyclic 
GMP levels were measured as described under “Materials and Meth- 
ods.” Each bar is the mean (?S.E.) for 3 determinations. We have 
tested nitroprusside on lobster muscle at many additional times and 
concentrations, without effect in all cases. See text for details. c, 
homogenates of rat aorta or lobster muscle were tested in the standard 
assay for nitroprusside sensitivity. The bars show net synthesis of 
cyclic GMP after 10 min in the presence (+NP) or absence (-NP) of 
0.3 mM nitroprusside (mean + range for duplicate determinations). 
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muscle (Fig. 5~). These tissues have been shown in other 
studies to contain a functioning EDRF pathway (Wood et al., 
1989; Furchgott and Vanhoutte, 1989). The nitroprusside data 
suggest strongly that the EDRF pathway not only does not 
mediate the effects of CHH, but, in fact, is probably not even 
expressed in lobster muscle. 
DISCUSSION 
From previous studies, many lines of evidence suggest that 
cyclic GMP metabolism plays a significant regulatory role in 
crustacean muscle. 1) The cytoplasmic levels of cyclic GMP 
in lobster muscle are much higher than the levels in compa- 
rable vertebrate tissues (Goy et al., 1987a). 2) The tissue 
content of cyclic GMP-dependent protein kinase is among 
the highest measured in any species (Kuo and Greengard, 
1970; Kuo and Shoji, 1982). 3) Endogenous substrates for 
cyclic GMP-dependent protein kinase are readily demon- 
strated in lobster muscle (Goy et al., 1984), although they 
have been difficult to find in vertebrate animals (Nairn and 
Greengard, 1983). 4) The sinus gland, a prominent lobster 
neurosecretory organ, contains a peptide (CHH) that dramat- 
ically increases the cyclic GMP levels of lobster muscle, and 
other lobster tissues as well (Sedlmeier and Keller, 1981; Goy 
et al., 1987a). 5) CHH regulates glycogen metabolism in 
crustacean muscle (Keller and Andrew, 1973). Preliminary 
data also suggest that CHH may alter the contractility of 
lobster muscle, perhaps by modifying excitation-contraction 
coupling (Goy et al., 1987b). 
The experiments in this paper have addressed the mecha- 
nism by which CHH mobilizes cyclic GMP metabolism in the 
neuromuscular target. The observations in Fig. 1 are consist- 
ent with the idea that in lobster muscle, as in other tissues, 
the level of cyclic GMP at any time reflects the relative rates 
of the cyclase and phosphodiesterase enzymes. The equilib- 
rium level can be raised by inhibiting the phosphodiesterase 
with IBMX. It can also be raised by treating the tissue with 
CHH, either in the presence or absence of the phosphodies- 
terase inhibitor. The enhancement of the peptide’s actions by 
IBMX suggests that the peptide acts primarily by stimulating 
one or both of the cyclases rather than by inhibiting a phos- 
phodiesterase enzyme. The data do not, however, rigorously 
exclude the phosphodiesterases from all aspects of the re- 
sponse. Parallel regulation of the phosphodiesterase could, for 
example, serve to amplify the cyclase response (or act in a 
negative feedback loop to limit it). 
One of the primary contributions of this work is the dem- 
onstration that CHH is capable of stimulating guanylate 
cyclase activity in isolated membranes (Fig. 4). This provides 
a plausible mechanism by which the peptide might carry out 
its biochemical actions in intact cells. It also places the peptide 
in the company of a relatively small number of biological 
activators of the cyclic GMP cascade. To date, only the 
mutually homologous members of the ANP family (Leitman 
and Murad, 1987; Song et al., 1988), ACTH (Nambi and 
Sharma, 1981), and a pair of sea urchin peptides called speract 
and resact (Hansbrough and Garbers, 1981; Suzuki et al., 
1984), have been shown to activate the membrane cyclase. A 
variety of cross-linking, purification, and cloning studies sug- 
gest that the receptors for these peptides in fact comprise an 
extracellular domain of the cyclase enzyme itself (reviewed in 
Schulz et al., 1989). This ligand binding domain appears to 
communicate with an intracellular catalytic domain by means 
of a single membrane-spanning helix. It will be important to 
determine whether the same is true of the CHH receptor in 
the lobster. Since there is no sequence homology between 
CHH and the peptides of the ANP, ACTH, or speract/resact 
families, it is apparent that the peptide recognition compo- 
nent associated with the lobster cyclase cannot be identical 
with those in vertebrates or sea urchins. However, the fact 
that the sequence of the catalytic component of the cyclase is 
maintained across all species tested suggests that the con- 
served regions of the molecule could be used to clone the 
lobster cyclase gene(s). This would establish a novel member 
of the guanylate cyclase family for comparative structure/ 
function analysis and would provide an additional vantage 
point for evaluating evolutionary constraints on the structure 
of the membrane cyclase. 
We have tried to address the question of whether CHH 
might, in addition, make use of the cytoplasmic form of 
guanylate cyclase, which is reasonably abundant in lobster 
muscle. Although we cannot entirely exclude a contribution 
of the soluble cyclase to the receptor-mediated response, Fig. 
5 strongly suggests that if coupling occurs between peptide 
receptors and the soluble cyclase then it does not occur by 
means of the EDRF pathway. In fact, the EDRF pathway 
appears not to function at all in lobster muscle, since a dose 
of nitroprusside that causes more than an 80-fold increase in 
the cyclic GMP level of cultured rat sensory neurons has no 
effect on isolated lobster muscle. This is somewhat unex- 
pected, since the ability to respond to nitroprusside is one of 
the hallmarks of the vertebrate cytoplasmic cyclase. It re- 
mains to be seen whether the lobster-soluble enzyme displays 
other significant differences from the vertebrate enzyme. 
If the EDRF pathway is not active in the lobster, then the 
existence of significant levels of cytoplasmic cyclase is some- 
what puzzling. The cytoplasmic enzyme is clearly distinct 
from the membrane cyclase, since it does not sediment at 
100,000 X g, is not coupled to CHH receptors, and does not 
show the time-dependent inactivation that is characteristic of 
the membrane form. In this regard, we do not know whether 
the lobster soluble cyclase is the product of a unique gene, or 
a degradation product resulting, for example, from proteolytic 
cleavage of the membrane cyclase. However, in either case, it 
seems likely that the soluble form is a natural component of 
intact tissue, rather than an artifact of homogenization, since 
the ratio of membrane to soluble cyclase remains constant 
even if we greatly prolong the interval between homogeniza- 
tion and centrifugation.’ This raises the question of the func- 
tional significance of the soluble cyclase in intact tissue. 
Several possibilities should be considered. 1) Perhaps CHH 
(or some other lobster hormone) stimulates the soluble cyclase 
by means of a coupling factor distinct from EDRF. 2) Perhaps 
the soluble cyclase is tonically active in a resting cell, but is 
inhibited following exposure to agents that raise intracellular 
Ca*+ (as in Figs. 2c and 3), thus leading to a decrease in cyclic 
GMP levels. 3) Perhaps the cytoplasmic form is an interme- 
diate in the degradation of the membrane cyclase and serves 
no other biological role. 
Whatever explanation proves to be correct, it is clear that 
describing the properties of the cyclic GMP system is essential 
to our basic understanding of metabolic regulation in the 
lobster. It is also apparent that structural and functional 
comparison of the guanylate cyclases of the lobster (both 
soluble and membrane) to those of vertebrate animals remains 
a fruitful area for further enquiry. 
Acknomledgments-I am greatly indebted to R&my Coyeteaux, 
David Lindquist, and Nelson Sinback for expert technical assistance. 
I thank Sara Raulerson, Cara Geary, and Dan McGehee for perform- 
ing some of the experiments reported here, and also I thank Kathleen 
Dunlap, Alan Willard, and Dan McGehee for reviewing an early draft 
of the manuscript. 
Peptide Stimulation of Particulate Guunylate Cyclase 20227 
REFERENCES 
Beavo, J. A. (1988) Adu. Second Messenger Phosphoprotein Res. 22, 
l-38 
Bergstrand, H., Kristoffersson, J., Lundquist, B., and Schurmann, A. 
(1977) Mol. Pharmacol. 13, 38-43 
Casnellie, J. E., and Greengard, P. (1974) Proc. N&l. Acad. Sci. U. S. 
A. 71, 1891-1895 
Craven. P. A.. and DeRubertis. F. R. (1978) J. Biol. Chem. 253. 
8433-8443 
Fischmeister, R., and Hartzell, H. C. (1987) J. Physiol. 387, 453-472 
Furchaott, R. F., and Vanhoutte. P. M. (1989) FASEB J. 3. 2007- 
2018 
Gammon, C. M., Allen, A. C., and Morel& P. (1989) J. Neurochem. 
53,95-101 
Garthwaite, J., Charles, S. L., and Chess-Williams, R. (1988) Nature 
336,385-388 
Goldberg, N. D., and Haddox, M. K. (1977) Annu. Reo. Biochem. 46, 
823-896 
Goy, M. F., and Kravitz, E. A. (1989) J. Neurosci. 9, 369-379 
Goy, M. F., Schwarz, T. L., and Kravitz, E. A. (1984) J. Neurosci. 4, 
61 l-626 
Goy, M. F., Mandelbrot, D. A., and York, C. M. (1987a) J. Neurochen. 
48, 954-966 
Goy, M. F., Kuo, M. H.-F., Pavloff, M., and Kravitz E. A. (198713) 
Neurosci. Abstr. 13, 1257 
Griffith, T. M., Lewis, M. J., Newby, A. C., and Henderson, A. H. 
(1988) J. Am. Coil. Cardiol. 12, 797-806 
Gruetter, C. A., Barry, B. K., McNamara, D. B., Gruetter, D. Y., 
Kadowitz, P. J., and Ignarro, L. J. (1979) J. Cyclic Nucleotide Res. 
5, 211-224 
Hamet, P., Tremblay, J., Pang, S. C., Skuherska, L., Schiffrin, E. L., 
Garcia, R., Cantin, M., Genest, J., Palmour, R., Ervin, F. R., 
Martin, S., and Goldwater, R. (1986) J. Hypertens. 4 (suppl.) s49- 
~56 
Hansbrough, J. R., and Garbers, D. L. (1981) J. Biol. Chem. 256, 
1447-1452 
Huberman, A., and Aguilar, M. B. (1986) Comp. Biochem. Physiol. B 
Comp. Biochem. 85, 197-203 
Ignarro, L. J., Buga, G. M., Wood, K. S., Burns, R. E., and Chaudhuri, 
G. (1987) Proc. N&l. Acad. Sci. U. S. A. 84, 9265-9269 
Kegel, G., Reichwein, B., Weese, S., Gaus, G., Peter-Katalinic, J., 
and Keller, R. (1989) FEBS Lett. 255, lo-14 
Keller, R., and Andrew, E. M. (1973) Gen. ComD. Endocrinol. 20. 
572-578 
Keller, R., Jaros, P. P., and Kegel, G. (1985) Am. Zool. 25, 207-221 
Kuo, J. F., and Greengard, P. (1970) J. Biol. Chem. 245, 2493-2498 
Kuo, J. F., and Shoji, M. (1982) Handb. Exp. Pharmacol. 58, 393- 
424 
Leitman, D. C., and Murad, F. (1987) End. Metab. Clin. North Am. 
16,79-105 
Leitman, D. C., Agnost, V. L., Tuan, J. J., Andresen, J. W., and 
Murad, F. (1987) Biochem. J. 244,69-74 
Lincoln, T. M., and Johnson, R. M. (1984) Adu. Cyclic Nucleotide 
Protein Phosphorylation Res. 17, 285-296 
Lowry, 0. H., Rosebrough, N. J., Farr, A. L., and Randall, R. 3. (1951) 
J. Biol. Chem. 193,265-275 
Martell, A. E., and Smith, R. M. (1974) Critical Stability Constants, 
Vol. 1, pp. 204-206, Plenum Publishing Co., New York 
Martell, A. E., and Smith, R. M. (1975) Critical Stability Constants, 
Vol. 2, p. 290, Plenum Publishing Co., New York 
Myers, P. R., Minor, R. L., Jr., Guerra, R., Jr., Bates, J. N., and 
Harrison, D. G. (1990) Nature 345, 161-163 
Nairn, A. C., and Greengard, P. (1983) Fed. Proc. 42,3107-3113 
Nambi. P.. and Sharma. R. K. (1981) Endocrinologv 108.2025-2027 
Newcomb; R. W. (19833 J. Comp. Physiol. 153, 207-221' 
Palmer, R. M. J., Ferrige, A. G., and Moncada, S. (1987) Nature 327, 
524-526 
Pavloff, M. S., and Goy, M. F. (1990) J. Neurochem. 55, 788-797 
Rapoport, R. M., Draznin, M. B., and Murad, F. (1982) Proc. Natl. 
Acod. Sci. U. S. A. 79,6470-6474 
Saper, C. B., Standaert, D. G., Currie, D. G., Schwartz, D., Geller, D. 
M., and Needleman, P. (1985) Science 227,1047-1049 
Schulz, S., Chinkers, M., and Garbers, D. L. (1989) FASEB J. 3, 
2026-2035 
Sedlmeier, D., and Keller, R. (1981) Gen. Comp. Endocrinol. 45, 82- 
90 
Seidah, N. G., Lazure, C., Chretien, M., Thibault, G., Garcia, R., 
Cantin, M., Genes& J., Nutt, R. F., Brady, S. F., Lyle, T. A., 
Paleveda, W. J., Colton, C. D., Ciccarone, T. M., and Veber, D. F. 
(1984) Proc. Natl. Acud. Sci. U. S. A. 81, 2640-2644 
Song, D.-L., Kohse, K. P., and Murad, F. (1988) FEBS Lett. 232, 
125-129 
Stryer, L. (1986) Annu. Reu. Neurosci. 9, 87-119 
Sudoh. T.. Kananawa, K., Minamino. N.. and Matsuo. H. (1988) 
Nature $32,7a81 
Suzuki, N., Shimomura, H., Radany, E. W., Ramarao, C. S., Ward, 
G. E., Bentley, J. K., and Garbers D. L. (1984) J. Biol. Chem. 259, 
14874-14879 
Tanaka, I., Misono, K. S., and Ingami, T. (1984) Biochem. Biophys. 
Res. Commun. 124,663-668 
Tremblay, J., Gerzer, R., and Hamet, P. (1988) Adu. Second Messen- 
ger Phosphoprotein Res. 22, 319-383 
Waldman, S. A., and Murad, F. (1987) Pharmacol. Reu. 39, 163-196 
Waldman, S. A., Rapoport, R. M., Fiscus, R. R., and Murad, F. (1985) 
Biochim. Biophys. Acta 845, 298-303 
Wood, J. N., Coote, P. R., Minhas, A., Mullaney, I., McNeill, M., and 
Burgess, G. M. (1989) J. Neurochem. 53, 1203-1211 
